ISHLT2025: Industry Symposia - Monday

Abbott

Primary Core Therapy: Heart | Primary Practice Area: Cardiology

Put Time on Your Side with Advanced HF Management

Join this timely discussion about how changing traditional LVAD strategies can optimize outcomes and put more time on advanced heart failure patients’ side.

Moderator

Jennifer Cowger, MD, MS, FACC, Henry Ford Health, Detroit, MI USA

Program

Extending Time: Optimizing outcomes with combination HF therapies

Ezequiel Molina, MD, Piedmont Healthcare, Atlanta, GA USA

Time to Take a New Look: Considerations in LVAD Patient Selection

Melana Yuzefpolskaya, MD, Columbia University Medical Center, New York, NY USA

The Time is Now: Advanced HF Therapy Patient education

Dmitry Yaranov, MD, Baptist Memorial Hospital, Memphis, TN USA

Evaluating the Referral Patient Pathway

Jennifer Cowger, MD, MS, FACC, Henry Ford Health, Detroit, MI USA

Q&A

All speakers

CareDx

From Bench to Bedside: Is Lung Transplant Ready for the dd-cfDNA Revolution?

Primary Core Therapy: Lung | Primary Practice Area: Pulmonology

This session will review extended applications of molecular testing to expanded clinical scenarios and patient populations, as well as new data from multi-modality testing in lung transplant recipients and a first look at the latest data from one of the largest registries of molecular testing in lung transplant.

Moderator

Jake Natalini, MD, NYU Grossman School of Medicine, New York, NY USA

Speakers

Samuel Weight, MD, University of California Los Angeles, CA USA
Ciara Shaver, MD, PhD, Vanderbilt University, Nashville, TN USA
Juan Fernandez Castillo, MD, Miami Transplant Institute / Jackson Memorial Hospital, Miami, FL USA

Johnson & Johnson

Expert Discussion: Emerging Evidence on a PAH Treatment

Primary Core Therapy: Lung | Primary Practice Area: Pulmonology

This program will feature a panel of pulmonary arterial hypertension (PAH) thought leaders, who will discuss concepts around risk assessment, pivotal trial data and two post hoc analyses, as well as real world evidence in patients with PAH.

This promotional educational activity is brought to you by Johnson & Johnson and is not certified for CME. The consultants are paid speakers for Johnson & Johnson. The speakers are presenting on behalf of Johnson & Johnson and must present information in compliance with FDA requirements applicable to Johnson & Johnson.

Moderator

John Ryan, MD, University of Utah, Salt Lake City, UT USA

Speakers

Mrinalini Krishnan, MD, Medstar Washington Hospital Center, Washington, DC USA
J. Wesley McConnell, MD, Norton Healthcare, Louisville, KY USA

Paragonix

Revolutionary Measures: Transformative Innovations Reshaping Lung Preservation

Primary Core Therapy: Lung | Primary Practice Area: Cardiothoracic Surgery

This session will provide a comprehensive overview of the latest findings from the GUARDIAN Lung Registry, along with case studies showcasing innovative applications of Paragonix Advanced Lung Preservation technology.

Join leading experts as they explore current trends in advanced lung preservation and transplantation, highlighting groundbreaking techniques designed to enhance organ viability and improve patient outcomes. Discover what’s next in the field as experts share their vision for the future of lung preservation and its role in expanding access to life-saving transplants.

Moderator

Michael Tajima, Paragonix Technologies, Waltham, MA USA

Program

Thriving Under Pressure: Lung Preservation Using Airway Pressure Control

Errol Bush, MD, FACS, Johns Hopkins University, Baltimore, MD USA

Frequent Flyer: Program Growth Through Adoption of Advanced Technologies

Rajat Walia, MD, FCCP, Norton Thoracic Institute / St. Joseph's Hospital & Medical Center, Phoenix, AZ USA

OPO Driven Pilot to Place More Donor Lungs with BAROguard

Sherry Quire, RN, MBA, BSN, Indiana Donor Network, Indianapolis, IN USA

Takeda

Novel Antivirals for Refractory or Resistant CMV Infection: Improving the Standard of Care for Solid Organ Transplant Recipients

Primary Core Therapy: Pulmonary Vascular Disease | Primary Practice Area: Infectious Diseases

Join us for a live 1-hour symposium focused on the use of novel antivirals for refractory or resistant cytomegalovirus (CMV) infection in solid organ transplant (SOT) recipients. In this program, specifically designed for healthcare providers involved in the care of SOT recipients, our expert faculty will discuss definitions of and risk factors for CMV infection in this patient population. They also will review the latest clinical trial and real-world data and how they navigate the evolving antiviral treatment landscape to optimize long-term patient outcomes.

Moderator

Emily Blumberg, MD, Hospital of the University of Pennsylvania, Philadelphia, PA USA

Program

Introduction

Emily Blumberg, MD, Hospital of the University of Pennsylvania, Philadelphia, PA USA

Examining Unmet Treatment Needs of SOT Recipients with CMV Infections

Camille Kotton, MD, FIDSA, FAST, Massachusetts General Hospital, Boston, MA USA

Resolving Refractory, Resistant CMV Infections – A Review of the Latest Clinical Trial, Real-World Data

Cameron Wolfe, MBBS, MPH, FIDSA, FAST, Duke Univesity School of Medicine, Durham, NC USA

Combatting a Menace, Victoriously: Improving the Standard of Care for SOT Recipients with Refractory or Resistant CMV Infection

All Faculty

Q&A

All Faculty

TransMedics

TransMedics Organ Care System (OCS) Next-Gen Heart and Lung Clinical Innovations

Primary Core Therapy: Heart | Primary Practice Area: Cardiothoracic Surgery

This session will include updates on the OCS clinical use, presentation of the new clinical programs and review of the data supporting the clinical programs.

Moderators

Kenneth McCurry, MD, Cleveland Clinic Foundation, Cleveland, OH USA
Carmelo Milano, MD, Duke University, Durham, NC USA

Program

Novel OCS Perfusion Solution & Enhancing Heart Function on OCS – Beyond Preservation

David Kaczorowski, MD, University of Pittsburg Medical Center, Pittsburgh, PA USA

2000+ OCS Heart Transplants - Update from the OHP Registry

Maryjane Farr, MD, MSc, UT Southwestern, Dallas, TX USA

OCS Lung Offers Excellent Outcomes with DCD Donor Lungs – The New Donor Paradigm

Ramiro Fernandez, MD, Texas Heart Institute, Houston, TX USA

Novel OCS Perfusion Solution & OCS Lung System – Deriving Superior Outcomes

Farhan Zafar, MDTransmedics, Andover, MA USA

Next-Gen OCS Heart and Lung Clinical Programs – The Future is Now

Waleed Hassanein, MD, Andover, MA USA

Panel Discussion and Q&A

Led by Moderators